Real-World Outcomes And Safety Of Pyrotinib In Her2-Positive Metastatic Breast Cancer (Mbc) Patients: A Prospective Cohort Study

Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows promising antitumor activity and acceptable tolerability in phase II and phase III randomized clinical trials. However, the real-world data of pyrotinib have been rarely reported. Here, we assessed the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive MBC patients.